Antimalarial medication

Outlook on the Worldwide Anti-Malarial Drugs Industry to 2024 - Insights & Forecast with Potential Impact of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 30, 2020
Infectious diseases, Pharmaceutical, Health, Antimalarial medication

The "Global Anti-Malarial Drugs Market (by Drug Type, Anti-Malarial Activity, End-Users & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Anti-Malarial Drugs Market (by Drug Type, Anti-Malarial Activity, End-Users & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.
  • Factors such as rising healthcare expenditure, increasing awareness about diseases, growing population and expanding urbanization are expected to drive the global anti-malarial drugs market.
  • The growth of the market would be challenged by an upsurge in drugs counterfeiting incidents, side effects of anti-malarial drugs and anti-malarial drug resistance.
  • The global anti-malarial drugs market is segmented on the basis of drug type, antimalarial activity and end-users.

Hydroxychloroquine Has about 90 Percent Chance of Helping COVID-19 Patients, States Association of American Physicians and Surgeons (AAPS)

Retrieved on: 
Tuesday, April 28, 2020
Chloroarenes, Quinolines, RTT, Health, Articles, Hydroxychloroquine, Association of American Physicians and Surgeons, AAPS, Pharmacy, Pharmacist, Antimalarial medication, Physician

Doug Ducey of Arizona, the Association of American Physicians and Surgeons (AAPS) presents a frequently updated table of studies that report results of treating COVID-19 with the anti-malaria drugs chloroquine (CQ) and hydroxychloroquine (HCQ, Plaquenil).

Key Points: 
  • Doug Ducey of Arizona, the Association of American Physicians and Surgeons (AAPS) presents a frequently updated table of studies that report results of treating COVID-19 with the anti-malaria drugs chloroquine (CQ) and hydroxychloroquine (HCQ, Plaquenil).
  • There were 63 deaths, all but 11 in a single retrospective report from the Veterans Administration where the patients were severely ill.
  • Most states are making it difficult for physicians to prescribe or pharmacists to dispense these medications.
  • The Association of American Physicians and Surgeons (AAPS) has represented physicians of all specialties in all states since 1943.

Global Anti-Malarial Medicines Market (2020 to 2024) - Drivers, Challenges and Trends - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 14, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Antimalarial medication, Trend

The "Global Anti-Malarial Medicines Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Anti-Malarial Medicines Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • The publisher has been monitoring the anti-malarial medicines market and it is poised to grow by $ 310.75 mn during 2020-2024 progressing at a CAGR of 6% during the forecast period.
  • The reports on the anti-malarial medicines market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.

Global Anti-malarial Medicines Market 2020-2024 | Evolving Opportunities with AstraZeneca Plc and Bayer AG | Technavio

Retrieved on: 
Tuesday, April 14, 2020
Health, Pharmaceutical, Health, Articles, Pharmaceuticals policy, Antimalarial medication, Pharmaceutical industry in China, Bayer, Medication, Pharmaceutical industry

The global anti-malarial medicines market is expected to grow by USD 310.75 million as per Technavio.

Key Points: 
  • The global anti-malarial medicines market is expected to grow by USD 310.75 million as per Technavio.
  • In addition, the persistent fight against COVID-19 is also propelling other nations such as the US to import of these anti-malarial medicines, thus contributing to the market growth.
  • In addition, the availability of enhanced POC diagnostics and biomarkers for malaria is anticipated to boost the growth of the anti-malarial medicines market.
  • Bayer AG offers products through the following business units: Pharmaceuticals, Crop Science, Consumer Health, and Animal Health.

Cigna Helps Accelerate Research For A COVID-19 Treatment By Donating Medications To Washington University School Of Medicine's Clinical Trial

Retrieved on: 
Thursday, April 9, 2020
Bloomfield, Connecticut, Cigna, Companies, Express Scripts, Antimalarial medication, Pharmacy, Economy of the United States

BLOOMFIELD, Conn., April 9, 2020 /PRNewswire/ --To accelerate research for a COVID-19 treatment, Cigna is providing medications to Washington University School of Medicine in St. Louis to initiate a clinical trial that will evaluate antimalarial and antibiotic treatments for COVID-19.

Key Points: 
  • BLOOMFIELD, Conn., April 9, 2020 /PRNewswire/ --To accelerate research for a COVID-19 treatment, Cigna is providing medications to Washington University School of Medicine in St. Louis to initiate a clinical trial that will evaluate antimalarial and antibiotic treatments for COVID-19.
  • "Finding a proven treatment for COVID-19 is the most pressing global public health priority," said Dr. Steve Miller, MD, Chief Clinical Officer, Cigna.
  • "Through our close collaboration with Washington University, we can help fast-track this effort."
  • Express Scripts, a Cigna company, unlocks new value in pharmacy, medical and beyond to further total health for all.

65 Percent of Physicians in New Survey Would Give Anti-Malaria Drugs to Their Own Family to Treat COVID-19

Retrieved on: 
Wednesday, April 8, 2020
Pharmaceutical industry, Antimalarial medication, Medication

Jackson & Coker conducted the survey of 1,271 physicians from 50 states from April 4 to April 7.

Key Points: 
  • Jackson & Coker conducted the survey of 1,271 physicians from 50 states from April 4 to April 7.
  • It conducted the survey not to influence the debate in treating patients with anti-malarials but to make sure the voice of physicians is represented.
  • The two anti-malaria drugs were given emergency approval for off-label usage by the Food and Drug Administration last week to treat COVID-19.
  • Jackson & Coker also found that 67 percent of surveyed physicians said they would take the medications themselves to treat COVID-19.

The Cardiac Risk of Chloroquine in Unapproved Indications

Retrieved on: 
Friday, March 27, 2020
RTT, Antimalarial medication, QT interval, Branches of biology, Chloroquine, Magnesium deficiency, QTC, Chemistry, Biology, Torsades de pointes, Drug-induced QT prolongation

Recently, the unapproved use of the antimalarial drug, chloroquine, has been touted as a treatment for COVID-19 with some reported deaths with its use in afflicted patients.

Key Points: 
  • Recently, the unapproved use of the antimalarial drug, chloroquine, has been touted as a treatment for COVID-19 with some reported deaths with its use in afflicted patients.
  • Because the QT interval is influenced by heart rate, it is most often given as the corrected QT interval or QTc.
  • Even therapeutic doses of chloroquine in healthy patients are associated with prolongation of QTc1, although this is generally well tolerated.
  • This is why chloroquine has specific warnings in its labeling to inform of the potential danger in patients with underlying risk factors (cardiac disease, hypokalemia, hypomagnesemia, bradycardia)3.

March 26 Statement: Lupus Research Alliance Puts Plaquenil Shortage Into Perspective For Lupus Community

Retrieved on: 
Thursday, March 26, 2020
RTT, Medical specialties, Chemical compounds, Chloroarenes, Quinolines, Organic compounds, Autoimmune diseases, Cutaneous lupus erythematosus, Systemic lupus erythematosus, Antimalarial medication, Hydroxychloroquine, Chloroquine

Thrust into the spotlight has been news about the potential benefit of anti-malarial drugs commonly used for lupus, hydroxychloroquine (brand name Plaquenil) and chloroquine, in treating COVID-19.

Key Points: 
  • Thrust into the spotlight has been news about the potential benefit of anti-malarial drugs commonly used for lupus, hydroxychloroquine (brand name Plaquenil) and chloroquine, in treating COVID-19.
  • The Lupus Research Alliance will continue to monitor the situation closely and push for continued access for people with lupus while working to ensure shortages abate in the future.
  • More than 90% of people with lupus are women; lupus most often strikes during the childbearing years of 15-45.
  • The Lupus Research Alliance aims to transform treatment while advancing toward a cure by funding the most innovative lupus research in the world.

The Quinism Foundation Calls on State Boards of Pharmacy to Enact Uniform Restrictions to Limit Hoarding of Quinoline Antimalarial Drugs Against COVID-19

Retrieved on: 
Monday, March 23, 2020
Chemical compounds, Organic compounds, RTT, Quinolines, Aromatic compounds, Chloroarenes, Quinoline, Antimalarial medication, Hydroxychloroquine, Quinine, Chloroquine, Mefloquine

WHITE RIVER JUNCTION, Vt., March 23, 2020 /PRNewswire-PRWeb/ --The Quinism Foundation has called on state boards of pharmacy to enact uniform restrictions on the dispensing of the quinoline antimalarial drugs hydroxychloroquine, chloroquine, mefloquine, primaquine, tafenoquine, and quinine to limit hoarding in response to the COVID-19 pandemic.

Key Points: 
  • WHITE RIVER JUNCTION, Vt., March 23, 2020 /PRNewswire-PRWeb/ --The Quinism Foundation has called on state boards of pharmacy to enact uniform restrictions on the dispensing of the quinoline antimalarial drugs hydroxychloroquine, chloroquine, mefloquine, primaquine, tafenoquine, and quinine to limit hoarding in response to the COVID-19 pandemic.
  • [1,2] "However, the same common properties that likely underlie the effectiveness of these quinoline antimalarial drugs against the virus may also underlie their common dangers."
  • "While hydroxychloroquine is among the safest drugs of the quinoline antimalarial class, all antimalarial quinolines share a common toxicity," said Dr. Nevin.
  • Dr. Nevin also emphasized that the Quinism Foundation has recently called on Congress to fund research into chronic quinoline encephalopathy.

The Quinism Foundation Calls on GSK to Take Action to Better Emphasize Limitations of Use for Krintafel® (Tafenoquine)

Retrieved on: 
Friday, February 28, 2020
Infectious diseases, Chemical compounds, Quinolines, Medical specialties, RTT, Malaria, Primaquine, Plasmodium vivax, Antimalarial medication, Pamaquine, Tropical diseases, 8-Aminoquinoline

Consequently, GSK must take appropriate action to better emphasize that approved use of Krintafel is limited to those receiving appropriate antimalarial therapy for acute P. vivax infection and that the drug is NOT indicated for presumptive anti-relapse therapy."

Key Points: 
  • Consequently, GSK must take appropriate action to better emphasize that approved use of Krintafel is limited to those receiving appropriate antimalarial therapy for acute P. vivax infection and that the drug is NOT indicated for presumptive anti-relapse therapy."
  • [4] "Publicly-available data support a conclusion that tafenoquine shares the liability to CNS neurotoxicity of related 8-aminoquinolines," said Dr. Nevin.
  • Dr. Nevin is a board-certified occupational medicine and preventive medicine physician and former U.S. Army medical officer and epidemiologist.
  • The effects of pentaquine,isopentaquine, primaquine, and pamaquine on the central nervous system of the rhesus monkey.